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Abstract: The carboxyl-terminal domain of the heavy chain of tetanus toxin (Hc-TeTx) exerts a
neuroprotective effect in neurodegenerative diseases via the activation of signaling pathways related
to neurotrophins, and also through inhibiting apoptotic cell death. Here, we demonstrate that Hc-TeTx
preserves motoneurons from chronic excitotoxicity in an in vitro model of amyotrophic lateral sclerosis.
Furthermore, we found that PI3-K/Akt pathway, but not p21ras/MAPK pathway, is involved in their
beneficial effects under chronic excitotoxicity. Moreover, we corroborate the capacity of the Hc-TeTx
to be transported retrogradely into the spinal motor neurons and also its capacity to bind to the
motoneuron-like cell line NSC-34. These findings suggest a possible therapeutic tool to improve
motoneuron preservation in neurodegenerative diseases such as amyotrophic lateral sclerosis.
Keywords: carboxyl-terminal domain of the heavy chain of tetanus toxin; neuroprotection;
excitotoxicity; spinal muscular atrophy; amyotrophic lateral sclerosis
Key Contribution: The carboxyl-terminal domain of the heavy chain of tetanus toxin (Hc-TeTx)
preserves motoneurons from chronic excitotoxicity thought PI3-K/Akt pathway.
1. Introduction
Motor neuron diseases (MNDs) are a group of neurodegenerative diseases which, despite
having different etiologies and clinical patterns, demonstrate that spinal motoneurons (MNs) are
selectively vulnerable. The most common form of MND in adults, amyotrophic lateral sclerosis (ALS),
is characterized by combined degeneration of upper and lower MNs, leading to progressive weakness
and death from respiratory failure a median of 30 months from symptom onset [1]. Most ALS cases
are apparently sporadic (sALS), though about 10% show familial inheritance (fALS), and specific
disease-determining mutations can be identified in up to 15% cases overall, with more than 50 genes
involved. ALS is currently incurable, with available therapies such as riluzole and edaravone only
having a trivial impact on disease progression [2,3]. Precision medicine based on approaches to therapy
in ALS is urgently needed [4].
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The carboxyl-terminal domain of the heavy chain of tetanus toxin (Hc-TeTx) is a non-toxic
fragment that binds to the cell membrane [5,6]. Several studies have demonstrated that Hc-TeTx
is able to preferentially bind to MNs [7–11], acting through lipid raft microdomains [12],
through gangliosides [13,14] and glycoprotein acceptors [15,16]. However, it is still unclear which
specific protein receptor mediates binding, although it is known that Hc-TeTx shares trafficking
vesicles with some neurotrophins and their receptors in being transported retrogradely to the central
nervous system [17]. Moreover, other functions have been described for the non-toxic domain of
tetanus toxin. Hc-TeTx can rescue cerebellar granule neurons from apoptotic cell death caused by
potassium deprivation and MPP+ toxicity [18,19], preserves MNs from acute excitotoxic damage [11],
and is an effective neuroprotective agent in several animal models of neurodegeneration [20,21],
including a mouse model of ALS [22–24]. Among the molecular mechanisms proposed for Hc-TeTx
neuroprotection are the p21ras/MAPK, PI3-K/Akt, and PLCγ/PKC signaling pathways which are
downstream of activation of tyrosine kinase receptors (Trks; tropomyosin-related kinases) [11,18,25,26].
However, further experiments are needed to clarify the molecular mechanisms underlying the
neuroprotective effects of Hc-TeTx. Here, we wanted to demonstrate the neuroprotective mechanisms
in a model of chronic excitotoxicity.
2. Results
2.1. Purification and Fluorescence Labeling of Recombinant Protein Hc-TeTx
In order to obtain a high-quality purification and fluorescence labeling of the recombinant
protein Hc-TeTx preparation for further therapeutic treatments and retroaxonal transport analysis,
we optimized the purification process of Hc-TeTx by using an FPLC system and cobalt-agarose
columns. We determined the eluted protein profile by measuring the absorbance at 280 nm (Figure 1A).
The chromatogram shows a wider peak that represents mixed proteins eluted, and the narrowest peak
represents the elution of the Hc-TeTx. The different fractions obtained during the process of purification
of the Hc-TeTx protein were treated under reducing conditions and resolved in an electrophoretic gel
by loading the same volume of each sample (15 µL). A large number of proteins were observed in
the wash fractions, whereas in the fractions corresponding to the narrowest peak, the presence of a
protein corresponding to a molecular weight of about 50 kDa was identified, such as Hc-TeTx protein.
The Hc-TeTx purity of the selected fractions represents around 70% (Figure 1B). Immunoblot with
the anti-histidine antibody allowed detecting the histidine tail of the C-terminal end of the Hc-TeTx
protein at 50 kDa (Figure 1C). In order to visualize Hc-TeTx by fluorescence, protein was attached to
the small molecule, Alexa Fluor®555. Labeled as Hc-TeTx-Alexa555, protein could also be detected
at 50 kDa under ultraviolet light (Figure 1D). Dual Color molecular weight markers indicated as M
allow detecting a band at 75 kDa and a band at 25 kDa under UV. Overall, these findings show that the
recombinant protein Hc-TeTx is produced at high purity and is specifically labeled by fluorescence.
2.2. Membrane Motoneuron Binding and Retrograde Transport of Recombinant Hc-TeTx Protein
In order to assess the capacity of the recombinant Hc-TeTx protein to be attached to MNs, we first
characterized the ability of the protein to bind to a motor neuron-like cell line, NSC34. We demonstrated
that upon addition of labeled Hc-TeTx to the culture, the protein was localized around the NSC-34
cells, suggesting that the incorporation of the fluorescence dye did not modify its capacity to binds to
MNs. Moreover, slight labeling can be seen in the soma of NSC-34 cells at 60 min which may be due to
the internalization of Hc-TeTx. However, further experiments with specific antibodies against TeTx are
needed to confirm this result (Figure 2A). Interestingly, binding to the cell membranes occurs in the
first 15 min after addition to the culture media. These results suggest that Hc-TeTx-Alexa555 maintain
its properties and it can be attached and may be internalized into MNs.
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Figure 1. Purification and fluorescence labeling methodology of the carboxyl-terminal domain of the 
heavy chain of tetanus toxin (Hc-TeTx) protein. (A) Elution profile of the Hc-TeTx protein. 
Electrophoresis SDS-PAGE stained with comassie blue and fast protein liquid chromatography 
(FPLC) chromatogram. (B) Densometric quantification of the eluted lanes corresponding to Hc-TeTx 
fractions. (C) Detection of the Hc-TeTx protein purified using the Western blot technique with the 
anti-histidine antibody. (D) Labeling detection of the Hc-TeTx protein conjugated to the Alexa 
Fluor®555 fluorochrome. Histogram and electrophoretic gel representing more than 30 purification 
processes carried out. 
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In order to assess the potential for a beneficial role of recombinant Hc-TeTx proteins in MND in 
vivo models, we wanted to analyze the capacity of our fluorescently labeled purified Hc-TeTx protein 
to be transported retrogradely into the central nervous system. Hc-TeTx were administered by focal 
injection into the right tibialis muscle (TA) of wild type mice at 50 ng/Kg to ensure enough protein 
would be transported into the ventral horn MN soma. At 24 h post-injection, Hc-TeTx can be localized 
at the neuromuscular junction (NMJ) of the right TA muscle, co-labeled with bungarotoxin (Figure 
2B). Moreover, we demonstrated that recombinant protein Hc-TeTx cannot diffuse to other muscles, 
such as neighboring gastrocnemius (GM), or muscles more remote from the injection site, such as the 
left TA and GM (Figure 2C), and it is inside the NMJ (Figure 2D). At 24 h, the recombinant protein 
injected into the right TA muscle can be detected in the corresponding ventral horn motor neuron 
pool innervating TA muscle (Figure 2E). However, further experiments with specific antibodies 
against TeTx are needed to confirm this result. These findings suggest that the intramuscular injection 
Figure 1. Purification and fluorescence labeling methodology of the carboxyl-terminal domain of
the heavy chain of tetanus toxin (Hc-TeTx) protein. (A) Elution profile of the Hc-TeTx protein.
Electrophoresis SDS-PAGE stained with comassie blue and fast protein liquid chromatography (FPLC)
chromatogram. (B) Densometric quantification of the eluted lanes corresponding to Hc-TeTx fractions.
(C) Detection of the Hc-TeTx protein purified using the Western blot technique with the anti-histidine
antibody. (D) Labeling detection of the Hc-TeTx protein conjugated to e Alexa Fluor®555 fluorochrome.
Histogram and electrophoretic gel represen ing more than 30 purification processes carried out.
In order to assess the potential for a beneficial role of recombinant Hc-TeTx proteins in MND
in vivo models, we wanted to analyze the capacity of our fluorescently labeled purified Hc-TeTx
protein to be transported retrogradely into the central nervous system. Hc-TeTx were administered
by focal injection into the right tibialis muscle (TA) of wild type mice at 50 ng/Kg to ensure enough
protein would be transported into the ventral h rn MN soma. At 24 h p st-injection, Hc-TeTx can be
localized at the neuromuscular junction (NMJ) of the right TA uscle, co-labeled with bungarotoxin
(Figure 2B). Moreover, we demonstrated that recombinant protein Hc-TeTx cannot diffuse to other
muscles, such as neighboring gastrocnemius (GM), or muscles more remote from the injection site,
such as the left TA and GM (Figure 2C), and it is inside the NMJ (Figure 2D). At 24 h, the recombinant
protein injected into the right TA muscle can be detected in the corresponding ventral horn motor
neuron pool innervating TA muscle (Figure 2E). However, further experiments with specific antibodies
against TeTx are needed to confirm this result. These findings suggest that the intramuscular injection
of recombinant Hc-TeTx protein can be internalized in the NMJ and transported retrogradely to the
spinal cord and is an effective method of delivery of a potentially neuroprotective agent with high
affi ity and specificity for spinal MNs for future studies in vivo.
Toxins 2020, 12, 666 4 of 11
Toxins 2020, 12, x FOR PEER REVIEW 4 of 11 
 
of recombinant Hc-TeTx protein can be internalized in the NMJ and transported retrogradely to the 
spinal cord and is an effective method of delivery of a potentially neuroprotective agent with high 
affinity and specificity for spinal MNs for future studies in vivo. 
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Time-course of Hc-TeTx-Alexa555 internalization in the NSC-34 cells, a motoneuron-like cell line. 
Controls performed by adding the same amount of fluorochrome did not show fluorescence at the 
indicated times. The bar represents 10 μm. (B) The Hc-TeTx-Alexa555 (red) protein is detected in motor 
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gastrocnemius muscles (GM) of the same leg (Left leg) or in the TA muscles and GM of the right leg, 
where there is no presence of Hc-TeTx-Alexa555. (D) At 24 h the Hc-TeTx-Alexa555 protein is located 
inside the NMJ without colocalizing with AChR receptors. The arrows indicate the formation of 
clusters inside the NMJ and presynaptic endings. Representative images of 3 independent 
experiments by condition. (E) Visualization of the Hc-TeTx-Alexa555 protein in the spinal cord at 24 h 
after intramuscular injection. The Hc-TeTx-Alexa555 protein (red) was visualized inside the soma of 
the motor neurons (green), which were marked with anti-SMI-32. The markup of Hc-TeTx-Alexa555 
followed a vesicular pattern. The control injection with the same amount of fluorocrom (Alexa 
Fluor®555) did not emit fluorescence in the spinal cord. 
2.3. Motor Neuron Preservation under Chronic Excitotoxicity 
In order to assess the neuroprotective capacity of recombinant Hc-TeTx protein, we first 
reproduced a well-established in vitro model of progressive chronic glutamate excitotoxicity by the 
addition of DL-threo-β-hydroxyaspartic acid (THA), an inhibitor of glutamate transport, using 
organotypic spinal cord slice cultures. After 7 days in vitro (DIV), we administered THA, 
accompanied by either vehicle or recombinant Hc-TeTx protein, at 10 nM, according to previous 
studies [13]. THA reduces MN numbers to about 60% in comparison to the control, but the addition 
of Hc-TeTx allows protecting the number of MNs, reaching 80% of MN preservation. In contrast, MN 
counting revealed that Hc-TeTx cannot enhance the number of MNs under basal culture conditions 
Figure 2. Internalization and retrograde transport of Hc-TeTx-Alexa555 protein on motoneurons.
(A) Time-course of Hc-TeTx-Alexa555 internalization in the NSC-34 cells, a motoneuron-like cell line.
Controls performed by adding the same amount of fluorochrome did not show fluorescence at the
indicated times. The bar represents 10 µm. (B) The Hc-TeTx-Alexa555 (red) protein is detected in motor
nerve endings ide tified with α-bungarotoxin (BGTX) (gr en) 24 h aft r single intramuscular injection
into the tibialis ant rior (TA) muscl . The injecti n with the same amount of fluorocrom (Alexa555)
does not emit fluorescence in the neuromuscular junction (NMJ). (C) The Hc-TeTx-Alexa555 protein
can be detected in the injected muscle but does not spread to other muscles such as gastrocnemius
muscles (GM) of the same leg (Left leg) or in the TA muscles and GM of the right leg, where there is
no presence of Hc-TeTx-Alexa555. (D) At 24 h the Hc-TeTx-Alexa555 protein is located inside the NMJ
without colocalizing with AChR receptors. The arrows indicate the formation of clusters inside the
NMJ and p esynapti endings. Representative images of 3 in ependent experim nts by condition.
(E) Visualization of the Hc-TeTx-Alexa555 protein in the spinal cord at 24 h after intramuscular injection.
The Hc-TeTx-Alexa555 protein (red) was visualized inside the soma of the motor neurons (green),
which were marked with anti-SMI-32. The markup of Hc-TeTx-Alexa555 followed a vesicular pattern.
The control injection with the same amount of fluorocrom (Alexa Fluor®555) did not emit fluorescence
in the spinal cord.
2.3. Motor Neuron Preservation under Chronic Excitotoxicity
In order t assess the neuroprote tive capaci y of recombinant Hc-TeTx protein, we first reproduced
a well-established in vitro model of progressive chronic glutamate excitotoxicity by the addition of
DL-threo-β-hydroxyaspartic acid (THA), an inhibitor of glutamate transport, using organotypic spinal
cord slice cultures. After 7 days in vitro (DIV), we administered THA, accompanied by either vehicle
or recombinant Hc-TeTx protein, at 10 nM, according to previous studies [13]. THA reduces MN
numbers to about 60% in comparison to the control, but the addition of Hc-TeTx allows protecting the
number of MNs, reaching 80% of MN preservation. In contrast, MN counting revealed that Hc-TeTx
cannot enhance the number of MNs under basal culture conditions (Figure 3). Given that chronic
excitotoxicity mediated by glutamate is implicated in the pathogenesis of ALS, these results indicate
that Hc-TeTx protein has the potential to act as a neuroprotective factor in ALS.
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acute excitotoxicity act via p21ras/MAPK and PI3-K/Akt signaling pathways [11]. Here, we found 
that the specific inhibitor for PI3-Kinases (LY294002) blocks the neuroprotective effect of Hc-TeTx 
under chronic excitotoxicity, but the inhibition of MEK1 (PD98059) did not block its beneficial effect 
(Figure 4A,B). Treatment of spinal cord cultures with both inhibitors under basal and excitotoxic 
conditions alone had no effect on MN survival. These findings suggest that recombinant Hc-TeTx 
protein exerts a neuroprotective role specifically through the PI3-K/Akt signaling pathway in an in 
Figure 3. Evaluation of the neuroprotective effect of the Hc-TeTx protein against chronic excitotoxic
damage caused by the addition of DL-threo-β-hydroxyaspartic acid (THA) (100 µM) in spinal cord
organotypic cultures. Motoneurons (MNs) located in the ventral horn of the spinal cord were visualized
by immunofluorescence with anti-SMI-32. The addition of THA (100 µM) at 7, 14, and 21 days
in vitro (DIV) caused a loss of MNs (C) with respect to the control (A). The treatment with Hc-TeTx
(10 nM) under conditions of chronic excitotoxicity allowed the viability of the MNs (D). There were
no differences in the viability of the MNs with treatment with Hc-TeTx under controlled conditions
(B). (E) Representative micrographs of the counting of positive SMI-32 cells in the ventral area of the
spinal cord. The values are shown according to ± SEM with a minimum of 15 sections per treatment.
On *** p < 0.001 and ** p < 0.01 with respect to THA (100 µM) according to an ANOVA analysis with
the statistical test of Bonferroni. The bar represents 50 µm.
2.4. Signaling Cascade Induced by Hc-TeTx under Chronic Excitotoxicity
Previously, we demonstrated that neuroprotective effects of recombinant Hc-TeTx protein after
acute excitotoxicity act via p21ras/MAPK and PI3-K/Akt signaling pathways [11]. Here, we found
that the specific inhibitor for PI3-Kinases (LY294002) blocks the neuroprotective effect of Hc-TeTx
under chronic excitotoxicity, but the inhibition of MEK1 (PD98059) did not block its beneficial effect
(Figure 4A,B). Treatment of spinal cord cultures with both inhibitors under basal and excitotoxic
conditions alone had no effect on MN survival. These findings suggest that recombinant Hc-TeTx
protein exerts a neuroprotective role specifically through the PI3-K/Akt signaling pathway in an in vitro
organotypic model of chronic excitotoxicity, which may have implications for targeting therapy in ALS.
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glutamate carriers by the addition of THA (100 μM) [28]. This ex vivo system is viewed as an 
established model of progressive excitotoxicity (slow excitotoxicity) and a very useful tool for the 
Figure 4. Hc-TeTx activates PI3-K/Akt signaling pathway in a chronic excitotoxicity model caused by
the addition of DL-threo-β-hydroxyaspartic acid (THA). Organotypic cultures were treated with the
glutamate transporter inhibitor (THA) at 100 µM and the Hc-TeTx protein at 10 nM. (A) Number of
SMI-32+ cells countered after addition of the MEK inhibitor, PD98059 at 100µM. (B) Number of SMI-32+
cells counted after addition of the PI3-K inhibitor, LY294002 at 50µM. While the PI3-K inhibitor blocks
the neuroprotective effect of Hc-TeTx protein, in the face of chronic excitotoxicity, the MEK inhibitor
does not impede this ability. The values are shown according to ± SEM with a minimum of 15 sections
per treatment. On *** p < 0.001, ** p < 0.01 and * p < 0.05 with respect to THA (100 µM) according to an
ANOVA analysis with the statistical test of Bonferroni.
3. Discussion
The preservation of MNs from cell death is a relevant goal in MNDs. In ALS, lack of early
biomarkers of disease activity is a barrier to initiating treatment early in disease, which is likely to be
the most therapeutically tractable phase. Several previous studies have suggested neuroprotective
effects of Hc-TeTx in a number of neurodegenerative diseases [20,21]. Moreover, recent studies have
demonstrated that Hc-TeTx promotes locomotor recovery and motor neuron survival after spinal cord
injury in rats, decreasing apoptotic markers of cell death and modulating autophagy [11,27]. We have
previously demonstrated that Hc-TeTx can promote the preservation of MNs under conditions of acute
excitotoxic damage [11].
Here, we demonstrated that Hc-TeTx can be easily produced at high purity. Conjugation with
fluorochromes facilitates easier tracking. In order to evaluate the potential neuroprotective effect
of Hc-TeTx protein in ALS, we used an organotypic spinal cord model based on the inhibition of
glutamate carriers by the addition of THA (100 µM) [28]. This ex vivo system is viewed as an
established model of progressive excitotoxicity (slow excitotoxicity) and a very useful tool for the
study of motor neuron degeneration. The origin of sporadic forms of ALS remains unclear, but it is
now recognized to be a multisystemic degeneration, involving multiple pathophysiological molecular
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processes, including excitotoxicity [4,29]. In patients with ALS, high levels of glutamate have been
detected in the cerebrospinal fluid (CSF), as well as low expression levels of the EAAT2 glutamate
transporter, although whether this is the cause of MN death or a consequence remains debated [30–32].
Glutamate carriers play a very important role in the buffering cells due to the toxic effects of excess
extracellular glutamate [33]. There is controversy around how chronically damaged motoneurons
die from excitotoxicity. During the degeneration of spinal MNs, apoptotic, necrotic, and autophagic
processes have been implicated, though the final common pathway of death of MNs may be mainly
due to apoptosis [34,35].
The beneficial role of Hc-TeTx in an in vitro model of glutamate excitotoxicity is due specifically
to the PI3-K/Akt signaling pathway. Hc-TeTx protein can also modulate autophagic pathways via
PI3-K/Akt [11]. Further experiments are needed to explore the capacity of recombinant Hc-TeTx protein
to preserve motoneurons and motor function in a mouse model of ALS such as SOD1G93A.
In the current study, we additionally wanted to highlight the capacity of fluorescently detecting
the Hc-TeTx recombinant protein to reveal its high capacity to be internalized in MNs and to be
transported retrogradely, supporting the potential of further in vivo experiments. Results from NSC34
cells reinforce the rapid capacity of Hc-TeTx to bind to MNs. Moreover, results in mice suggest that
Hc-TeTx can be transported retrogradely in just 24 h.
In summary, Hc-TeTx recombinant protein preserves MNs from chronic degenerative process,
specifically through the PI3-K/Akt signaling pathway. The capacity of Hc-TeTx to be transported
retrogradely suggests that further work should focus on studies to elucidate the protein partners by
which Hc-TeTx is transported at a faster rate than other retrotracers.
4. Materials and Methods
4.1. Recombinant Hc-TeTx Protein Purification
Escherichia coli BL21 cells were transformed by pQE3-Hc-TeTx-Hisx6 plasmid and cells were
grown in Luria Bertani medium containing 100 µg/mL ampicillin. Protein expression was induced
by the addition of 0.4 mM isopropyl β D thiogalactoside (IPTG). After 3 h, cells were pelleted by
centrifugation at 4000× g for 20 min at 4 ◦C, resuspended in lysis buffer (50 mM NaH2PO4, 300 mM
NaCl and 1% Triton ×100; pH 8) and sonicated on ice for six 30 s periods. The suspension was
centrifuged at 30,000× g for 30 min at 4 ◦C. The clear supernatant, which contains the His-tagged
protein, was purified by cobalt affinity chromatography. Mixed proteins were injected in a fast protein
liquid chromatography (FPLC), which contains a cobalt-agarose resin (TALON Metal Affinity resin,
Clontech Laboratories; Palo Alto, CA, USA), previously equilibrated (50 mM NaH2PO4 and 300 mM
NaCl; pH 7). The proteins, without His-Tags, were eluted by washing the resin with elution buffer
(50 mM NaH2PO4 and 300 mM NaCl; pH 7). Hc-TeTx contains six histidine residues and is retained
in the resin forming a Co-complex. Hc-TeTx was eluted with the elution buffer (50 mM NaH2PO4,
300 mM NaCl and 150 mM Imidazole; pH 7). Fractions collected were 0.5 mL in volume. The elution
process can be followed with an FPLC system that constantly measures the absorbance at 280 nm.
Protein was separated by sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) at
12%. Gel was stained with GelCode Blue Stain Reagent (Pierce Chemical Co.; Rockford, IL, USA) and
those fractions containing purified Hc-TeTx protein were dialyzed (40 mM Na2HPO4, 10 mM NaH2PO4
and 150 mM NaCl; pH 7.4) overnight at 4 ◦C and for 2 h with new buffer. Protein concentrations were
determined using the bicinchoninic acid assay (BCA, Pierce Chemical Co.; Rockford, IL, USA) and
lyophilized. The Hc-TeTx was stored in aliquots at −20 ◦C. Alexa Fluor®555 was attached to Hc-TeTx
following the manufacturer’s protocol from Alexa Fluor®555 Labeling Kit (Invitrogen; Carlsbad, CA,
USA) and stored at −20 ◦C.
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4.2. Hc-TeTx Retrogade Transport
Single intramuscular injection of Hc-TeTx-Alexa555 at 50 ng/kg was performed into the right
tibialis anterior muscle in wild-type (WT) adult mice to assess the capacity of the conjugated protein
to be retrogradely transported. After 24 h, right and left tibialis and gastrocnemius muscles were
collected and fixed in PFA 4%. Then, tissue was cryopreserved with sucrose at 4 ◦C.
4.3. NSC-34 Cell Culture
NSC-34 cells were grown in coated poly-D-lysine 24-well plates with 1 mL Glutamax with 10%
(v/v) FBS. Cells were plated at 2.5 × 105 cells/well for experiments. After 48 h, the medium was replaced
with Dubelcco Modified Eagle Medium (DMEM) plus 10% (v/v) FBS.
4.4. Spinal Cord Organotypic Culture
Organotypic spinal cord cultures were prepared from lumbar spinal cords of 8-day-old
Sprague-Dawley rat pups (P8), as previously described [13,29,30]. After euthanasia, the spinal
cord was collected under sterile conditions and placed in ice-cold high glucose-containing (6.4 mg/mL)
Gey’s Balanced Salt Solution (GBSS) (Sigma-Aldrich Corp.; St. Louis, MO, USA). Meninges and roots
were removed, and the spinal cord was transversely sectioned in 350 µm slices with a McIlwain
Tissue Chopper (The Mickle Laboratory Engineering Co.; Surrey, UK). Five sections were carefully
transferred on Millicell-CM porous membranes (0.4 µm) (Millipore; Billerica, MA, USA) into a 6-well
plate containing 1 m: of incubation medium (50% minimal essential medium (MEM), 25 mM Hepes,
25% heat-inactivated horse serum, 2 mM glutamine and 25% Hank’s Balanced Salt Solution (HBSS)
supplemented with 25.6 mg/mL glucose; pH 7.2). Cultures were incubated at 37 ◦C in a 5% CO2/95%
air humidified environment. Cultures were left to stabilize for one week, and after this, the medium
was changed twice per week until 28 days in vitro (DIV). Under these conditions, the MN population
reaches a steady number from one to four weeks, as previously described [30]. All procedures
involving animals were approved by the Ethics Committee of Universitat Autònoma de Barcelona
and followed the European Communities Council Directive 86/609/EEC. After 7 days of the explant
culture, chronic glutamate excitotoxicity will be induced by DL-threo-β-hydroxyaspartic acid (THA)
at 100 µM, 1 to 4 weeks, a potent glutamate transporter inhibitor, which is known to produce a
dose-dependent sustained elevation of glutamate levels, causing degeneration of motor neurons [28].
The neuroprotective effect of Hc-TeTx at 10 nM will be assessed by its co-addition to the culture with
THA and renewal of each medium change.
4.5. Motor Neuron Counting
We identified MNs in the slices by immunostaining with SMI-32 antibody and according to their
localization in the ventral horn of lumbar sections. All thoracic and sacral sections were excluded.
We blindly counted MNs meeting these criteria in each spinal cord section. To count SMI-32 positive
cells in the ventral horn of organotypic spinal cord slices, we used Z-stack confocal series.
4.6. Immunofluorescence
Spinal cord slices were fixed with 4% paraformaldehyde at room temperature for 1 h. Slices were
then washed twice with phosphate-buffered saline (PBS) for 15 min, blocked with 5% normal horse
serum and 0.2% Triton-X100 in PBS, and incubated overnight at 4 ◦C with antibody against mouse
anti-neurofilament heavy-chain (NF-H) (SMI-32, 1:1000) (Sternberger Monoclonals Inc.; Baltimore, MD,
USA). Cultures were then thoroughly washed in PBS with 0.2% Tween-20 (PBS-T) and incubated with
appropriate secondary antibody Alexa Fluor®488 goat anti-mouse IgG (1:1000) diluted in blocking
buffer for 1 h at room temperature. Then, slices were washed two times with PBS-T, incubated
for 20 min with DAPI (4′,6-Diamidino-2-phenylindole), diluted in PBS, and washed several times.
Finally, slices were mounted in Superfrost®Plus slides (Thermo Fisher Scientific; Waltham, MA, USA)
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with Fluoromount-G mounting medium (SouthernBiotech; Birmingham, AL, USA) and fluorescence
was visualized under an epifluorescence microscope (Nikon Eclipse 90i, Nikon Instruments Inc.;
Melville, NY, USA) or a confocal microscope (Leica TSC SP5, Leica Microsystems; Deerfield, IL, USA).
A minimum of 15 sections were used for MN counting for each experimental condition.
4.7. Statistical Analysis
Statistical significance was determined by one-way ANOVA, followed by Bonferroni’s post hoc
test. Differences were considered to be significant if p < 0.05.
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